Sale!

Pre-eclampsia Predictor sFLT-1PIGF Ratio Panel Test

700 د.إ

-10%

The “Pre-eclampsia Predictor sFLT-1/PlGF Ratio Panel Test” is a sophisticated diagnostic tool used to evaluate the risk of pre-eclampsia in pregnant women. This test measures the levels of two proteins in the blood: soluble fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PlGF). The ratio of these proteins can indicate the likelihood of developing pre-eclampsia, a potentially serious condition characterized by high blood pressure and signs of damage to another organ system, most often the liver and kidneys, during pregnancy.

Pre-eclampsia can lead to severe complications for both the mother and the baby if left undiagnosed or untreated. Early detection through the sFLT-1/PlGF ratio panel test allows for timely intervention, potentially reducing the risk of developing severe complications.

The test is available at DNA Labs UAE, a leading provider of genetic and diagnostic testing services in the United Arab Emirates. The cost of the test is 700 AED. DNA Labs UAE is known for its state-of-the-art facilities and commitment to providing accurate and reliable health information, making it a trusted choice for expecting mothers seeking to assess their risk for pre-eclampsia.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

PRE-ECLAMPSIA PREDICTOR sFLT-1PIGF RATIO PANEL Test

Test Name: PRE-ECLAMPSIA PREDICTOR sFLT-1PIGF RATIO PANEL Test

Components: PLGF, sFLT-1, PIGF RATIO

Price: 700.0 AED

Sample Condition: 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen.

Report Delivery: SampleTue / Thu /Sat by 9 am; Report Same Day

Method: ECLIA

Test type: Pre-eclampsia

Doctor: Gynecologist

Test Department: Pre Test Information

No special preparation required

Test Details

The PRE-ECLAMPSIA PREDICTOR (sFLT-1:PIGF RATIO) PANEL test is a diagnostic tool used to assess the risk of developing pre-eclampsia during pregnancy. Pre-eclampsia is a serious condition characterized by high blood pressure and damage to organs such as the liver and kidneys. It can be life-threatening for both the mother and the baby if left untreated.

The test measures the ratio of two proteins in the blood: soluble fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PIGF). In women with pre-eclampsia, the levels of sFLT-1 are increased, while the levels of PIGF are decreased. By comparing the ratio of these proteins, the test can provide an indication of the likelihood of developing pre-eclampsia.

The test is typically performed around the 20th week of pregnancy and can help healthcare providers identify women who may require closer monitoring or early intervention to prevent or manage pre-eclampsia. Early detection and management of pre-eclampsia can significantly improve outcomes for both the mother and the baby.

It is important to note that the PRE-ECLAMPSIA PREDICTOR (sFLT-1:PIGF RATIO) PANEL test is just one tool in the assessment of pre-eclampsia risk and should be used in conjunction with other clinical evaluations and tests. It is not a definitive diagnosis of pre-eclampsia but rather a tool to aid in risk assessment and decision-making.

Test Name PRE-ECLAMPSIA PREDICTOR sFLT-1PIGF RATIO PANEL Test
Components *PLGF*sFLT-1*PIGF RATIO
Price 700.0 AED
Sample Condition 2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen.
Report Delivery SampleTue / Thu /Sat by 9 am; Report Same Day
Method ECLIA
Test type Pre-eclampsia
Doctor Gynecologist
Test Department:
Pre Test Information No special preparation required
Test Details

The PRE-ECLAMPSIA PREDICTOR (sFLT-1:PIGF RATIO) PANEL test is a diagnostic tool used to assess the risk of developing pre-eclampsia during pregnancy. Pre-eclampsia is a serious condition characterized by high blood pressure and damage to organs such as the liver and kidneys. It can be life-threatening for both the mother and the baby if left untreated.

The test measures the ratio of two proteins in the blood: soluble fms-like tyrosine kinase-1 (sFLT-1) and placental growth factor (PIGF). In women with pre-eclampsia, the levels of sFLT-1 are increased, while the levels of PIGF are decreased. By comparing the ratio of these proteins, the test can provide an indication of the likelihood of developing pre-eclampsia.

The test is typically performed around the 20th week of pregnancy and can help healthcare providers identify women who may require closer monitoring or early intervention to prevent or manage pre-eclampsia. Early detection and management of pre-eclampsia can significantly improve outcomes for both the mother and the baby.

It is important to note that the PRE-ECLAMPSIA PREDICTOR (sFLT-1:PIGF RATIO) PANEL test is just one tool in the assessment of pre-eclampsia risk and should be used in conjunction with other clinical evaluations and tests. It is not a definitive diagnosis of pre-eclampsia but rather a tool to aid in risk assessment and decision-making.